Proteins and Peptides

06 Apr 2017 XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögren’s Syndrome
04 Apr 2017 ERYTECH Announces Launch of Investigator-Initiated Phase 2 Study of eryaspase (GRASPA®) for ALL
04 Apr 2017 Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting
04 Apr 2017 amcure Presents Preclinical Data on Lead Cancer Compound AMC303 at AACR Annual Meeting
03 Apr 2017 Versartis Reports New Data on Long-Acting Somavaratan in Growth Hormone Deficiency at ENDO 2017
03 Apr 2017 Genexine Releases Positive Interim Phase 2 Clinical Data from PGHD Trial with long-acting growth hormone, GX-H9 at ENDO 2017
03 Apr 2017 Teva Receives Positive Outcome for COPAXONE® 40 mg/ml 3 Times Weekly Label in Europe
03 Apr 2017 Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment
01 Apr 2017 Halozyme Provides Update On SWOG Collaborative Group Clinical Study
30 Mar 2017 ContraFect Awarded Funding from CARB-X to Support Gram-Negative Lysin Program
29 Mar 2017 ARMO BioSciences Announces First Patient Dosed in Pivotal Phase 3 Trial of Immunotherapy AM0010 for Advanced Pancreatic Cancer
29 Mar 2017 Novo Nordisk resubmits new drug application for fast-acting insulin aspart in the US
27 Mar 2017 Nektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, Being Developed for the Treatment of Immune and Inflammatory Disorders
27 Mar 2017 Synergy Pharmaceuticals Submits Supplemental New Drug Application (sNDA) for TRULANCE™ (Plecanatide) for the Treatment of Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
27 Mar 2017 ERYTECH Reports Positive Phase 2b Data for eryaspase for the Treatment of Metastatic Pancreatic Cancer
24 Mar 2017 EPREX® (epoetin alfa) Marketing Authorisation Extended to Include Treatment of Symptomatic Anaemia in Patients with Low or Intermediate-1-Risk Myelodysplastic Syndromes
24 Mar 2017 CHMP provides positive opinion for EU label update for Novo Nordisk's Tresiba® based on data from SWITCH trials
24 Mar 2017 Novo Nordisk receives positive opinion from the European regulatory authorities for Refixia® (nonacog beta pegol, N9-GP) for the treatment of haemophilia B
22 Mar 2017 Cue Biopharma Announces Selection of Lead Candidate Cue-101 Targeting Human Papillomavirus (HPV)-Associated Cancers
22 Mar 2017 Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
21 Mar 2017 WntResearch Announces Positive Results From Clinical Study With Drug Candidate Foxy-5
20 Mar 2017 BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment
16 Mar 2017 Shire Receives European Approval for Label Extension of CINRYZE®▼(C1 inhibitor ) to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE
16 Mar 2017 Helmsley Charitable Trust and Akston Biosciences Corporation Announce Partnership to Advance Novel Technology to Treat Type 1 Diabetes
14 Mar 2017 Lung Therapeutics, Inc. Doses First Patient in Phase 1 Clinical Trial of LTI-01 in Australia and New Zealand

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing